Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;25(7):464–468. [Article in Spanish] doi: 10.1016/S0212-6567(00)78545-3

Relación entre calidad y coste de la prescripción farmacológica en atención primaria

Relationship between quality and cost of pharmacological prescription in primary care

E Amado Guirado a,*, R Madridejos Mora a, M Pérez Rodríguez a, X Puig b
PMCID: PMC7679476  PMID: 10851750

Abstract

Objectives

With a system of qualitative indicators, to analyse the pharmaceutical prescription of general practitioners (GPs), and to evaluate the relationship of these indicators to the overall pharmaceutical prescription expenditure per inhabitant.

Design

Retrospective descriptive study.

Setting

Primary care.

Measurements and main results

The drugs prescription of 285 GPs from 32 primary care teams was evaluated, with the individual prescription of each doctor as the unit of analysis. The prescription was classified in 3 categories according to its intrinsic value (IV): low (. 75%), medium (76–79%) and high (. 80%). Selected as tracers of over-prescription were: daily dose per inhabitant (DDI) of antibiotics (AB), DDI of non-steroid anti-inflammatory drugs (NSAID), and DDI of ulcer drugs (ULC). Selected as tracers of selection were: % DDI third-generation cephalosporins/DDI total cephalosporins; % DDI broad-spectre quinolones/DDI total quinolones; and % DDI NSAID/DDI NSAID plus analgesics. Quantitative indicators studied were: total expenditure per allocated population, cost per drugs prescription of doubtful efficacy, and cost per daily dose of AB, NSAID and ULC. Variance analysis, including the Scheffe test for multiple comparisons and Pearson's linear correlation, was applied. 26% of the prescriptions had an IV below 75%, and 34% had an IV above 80%. The means of DDI of AB among the categories of IV were different (p < 0.0001), as were those of DDI of NSAID (p < 0.0001) and of ULC (p = 0.007). Lower consumption of AB, NSAID and ULC was found in prescriptions with the highest IV %. The third-generation cephalosporins and the NSAID + analgesics showed significant differences in the three IV categories (p < 0.0001 and p = 0.041), unlike broad-spectrum quinolones (p = 0.18). The total expenditure per allocated population was less for GPs whose prescriptions had the highest IV %; whereas the cost per prescription and cost per daily dose showed no significant differences for IV categories.

Conclusions

The doctors with the best qualitative profile on these indicators had less expenditure per inhabitant. However, no differences were found in the cost per prescription or cost per treatment between doctors. Therefore, interventions must prioritise improving drug prescription quality rather than just promoting changes to lower-cost drugs.

Bibliografía

  • 1.Anónimo La despesa en medicaments (1.a part) Butlletí Groc. 1996;9:17–22. [Google Scholar]
  • 2.Anónimo La despesa en medicaments (2.a part) Butlletí Groc. 1997;10:1–4. [Google Scholar]
  • 3.Zara C., SegúL L., Font M., Rovira J. La regulación de los medicamentos: teoría y práctica. Gac Sanit. 1998;12:39–49. doi: 10.1016/s0213-9111(98)76441-6. [DOI] [PubMed] [Google Scholar]
  • 4.Freemantle N., Bloor K. Lessons from international experience in controlling pharmaceutical expenditure I: influencing patients. BMJ. 1996;312:1469–1471. doi: 10.1136/bmj.312.7044.1469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bloor K., Freemantle N. Lesson from international experience in controlling pharmaceuticla expenditure II: influencing doctors. BMJ. 1996;312:1525–1527. doi: 10.1136/bmj.312.7045.1525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bloor K., Maynard A., Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry. BMJ. 1996;313:33–35. doi: 10.1136/bmj.313.7048.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Harris C.M., Heywood P.L., Clayden A.D. HMSO; Londres:: 1990. The analysis of prescribing. [Google Scholar]
  • 8.Audit Commission . HMSO; Londres:: 1994. A prescription for improvements: towards more rational prescribing in general practice. [Google Scholar]
  • 9.Saturno P.J. Monitorización del uso de medicamentos para mejorar la calidad de la prescripción: problemas, métodos e indicadores. Aten Primaria. 1996;18:331–338. [PubMed] [Google Scholar]
  • 10.Catalán A., Parellada N. La reforma de l'atenció primària i el consum de fàrmacs: una simbiosi, encara? Fulls Econòmics. 1997;30:12–18. [Google Scholar]
  • 11.Catalán A., Moreau F., Font M., Madridejos R., Farré J. Impacte de la reforma de l'atenció primària sobre la prescripció de fàrmacs. Revista Econòmica de Catalunya. 1991;16:43–46. [Google Scholar]
  • 12.Rey M., Villalbí J.R. Impacto potencial de la reforma de la atención primaria sobre la prescripción farmacéutica en España: la experiencia de Ciutat Badia. Med Clin (Barc) 1987;89:141–143. [PubMed] [Google Scholar]
  • 13.Jiménez A., Ordóñez M.V., Córdoba J.A., Fernández M.A. Factores relacionados con el gasto y la calidad de la prescripción farmacéutica en atención primaria. Aten Primaria. 1995;16:131–136. [PubMed] [Google Scholar]
  • 14.Amado E., Madridejos R., Pérez M.T., Catalán A. Análisis de la prescripción en atención primaria: evaluación de un sistema de indicadores. Aten Primaria. 1997;20:381–384. [PubMed] [Google Scholar]
  • 15.Laporte J.R., Tognoni G., editors. Principios de la epidemiología del medicamento. 2.a. Masson-Salvat; Barcelona:: 1993. [Google Scholar]
  • 16.WHO Collaborating Centre for Drug Statistics Methodology and Nordic Council of Medicine . WHO; Oslo:: 1996. Guidelines for DDD. [Google Scholar]
  • 17.MacGavock H. Strategies to improve the cost-effectiveness of general practitioner prescribing. Pharmacoeconomics. 1997;12:307–311. doi: 10.2165/00019053-199712030-00003. [DOI] [PubMed] [Google Scholar]
  • 18.Soumerai S.B., McLaughlin T.J., Avorn J. Quality assurance for drug prescribing. Quality Assurance in Health Caren. 1990;2:37–58. doi: 10.1093/intqhc/2.1.37. [DOI] [PubMed] [Google Scholar]
  • 19.Denig P., Haaijier-Ruskamp F. Do physicians take cost into account when making prescribing decisions? Pharmacoeconomics. 1995;8:282–290. doi: 10.2165/00019053-199508040-00003. [DOI] [PubMed] [Google Scholar]
  • 20.Juncosa S. ¿Deben los médicos generales considerar los costes de su prescripción? Gac Sanit. 1992;6:40–44. doi: 10.1016/s0213-9111(92)71091-7. [DOI] [PubMed] [Google Scholar]
  • 21.Redwood H. Pharmaceutical cost containment and quality care: conflict or compromise? Pharmacoeconomics. 1998;14(Supl 1):9–13. doi: 10.2165/00019053-199814001-00002. [DOI] [PubMed] [Google Scholar]
  • 22.Carpenter C.E., Bender A.D., Nash D.B. Must we choose between quality and cost containment? Qual Halth Care. 1996;5:223–229. doi: 10.1136/qshc.5.4.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Amado E., Pérez M.T., Madridejos R., Esteras J., Catalán A. Variabilidad de la prescripción por grupo terapéutico entre equipos de atención primaria. Comunicación presentada en el II Congreso de la SEFAP, San Sebastián. 1997;109 [Google Scholar]
  • 24.Tonks A. GPs prescribing is irrational, says Audit Commission (editorial) BMJ. 1994;308:675. [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES